Meet The NDAC, Minus One, As Conflict Of Interest Rules Come Into Play

New Nonprescription Drugs Advisory Committee member James Kehrer's expertise on acetaminophen toxicity should make him a key figure at FDA's upcoming meeting on the drug, he says